We next investigated the correlation between HPDL expression levels and the response to anti-PD-L1 immunotherapy in a pan-cancer cohort, including bladder cancer and the expression levels of anti-PD1 in melanoma (Figures 6C, 6D). This evidence concerns the gene HPDL and urinary bladder cancer.